NL-OMON40972RecruitingNot Applicable
A clinical pathway for older prostate cancer patients - Clinical Pathway Prostate Cancer
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- IVE
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •Diagnosis of prostate cancer
- •Age at least 65 and at least one chronic disease (of a list of 30 diseases of the RIVM);Specific criteria for the different treatment options:
- •After radical prostatectomy inclusion 1 year after operation if:
- •PSA < 0,1
- •No other active treatment by urologist (for example erectile dysfunction or incontinence)
- •After radiotherapy (in- or external) inclusion 1 year after radiotherapy if:
- •PSA declining
- •No other active treatment by urologist (for example erectile dysfunction or incontinence)
- •Watchful waiting inclusion 6 months after start watchful waiting if:
- •PSA stable
- •No other active treatment by urologist (for example erectile dysfunction or incontinence)
- •Hormone therapy inclusion 6 months after start hormone therapy if:
- •Health complaints absent or stable
Exclusion Criteria
- •- In active medical treatment
- •- After-care by GP not medically safe
- •- in the normal situation the patient would be checked by the urologist for at least one year
Investigators
Similar Trials
Completed
Not Applicable
Patient involvement in prostate cancer treatment decisionsCancerProstate cancerISRCTN97145188Dutch Cancer Society (The Netherlands)300
Recruiting
Not Applicable
The safety and efficacy of Irreversible Electroporation for the ablation of prostate cancer assessed by procedural related side effects and post prostatectomy histology: A pilot studyCancer - ProstateProstate cancerACTRN12612000523808Flack Trustees6
Recruiting
Not Applicable
Clinical study of prostate cancer dagnositic makers using genetic polymorphismsProstate cancerJPRN-UMIN000019278Kyoto University2,000
Recruiting
Phase 1
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 TrialProstate cancerCTIS2022-501551-90-00Gasthuiszusters Antwerpen493
Completed
Not Applicable
Transmurale zorg Prostaatkanker, van diagnose tot en met nazorgProstate cancer, transmural care, decision aid, SDM, Follow-up care, Substitution, Family doctors or General practitioners, Prostaatkanker, Keuzehulp, Samenwerking tussen eerste lijn en tweede lijn.NL-OMON22953Initiator: Catharina Wilhelmina Hospital (CWZ)NijmegenPrimary Sponsor/Performer: Radboud University Nijmegen Medical centerOther performers: CWZ in Nijmegen, Maashospital Pantein in Boxmeer200